Literature DB >> 8235690

Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.

W Plunkett1, V Gandhi, P Huang, L E Robertson, L Y Yang, V Gregoire, E Estey, M J Keating.   

Abstract

Knowledge of the pharmacokinetics of a drug is essential to the optimal design of the dose and schedule of chemotherapy protocols. As an extension, an understanding of the mechanism of drug action is necessary to construct the optimal strategy for combination chemotherapy. Nucleoside antimetabolites such as fludarabine are pro-drugs that must enter cells and be phosphorylated to the nucleoside triphosphate before they can elicit biologic activity. Thus, knowledge of the pharmacokinetics of the triphosphate in target cells and an understanding of the mechanisms by which this active form of the drug act are indispensable to the rational design of treatment protocols. This article reviews the essential elements of the pharmacokinetics and mechanisms of action of fludarabine to provide a rationale for combinations of fludarabine with other chemotherapeutic agents and anti-cancer modalities.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8235690

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  27 in total

1.  Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.

Authors:  Alma Zecevic; Deepa Sampath; Brett Ewald; Rong Chen; William Wierda; William Plunkett
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia.

Authors:  Kazutaka Takagi; Yasukazu Kawai; Takahiro Yamauchi; Hiromichi Iwasaki; Takanori Ueda
Journal:  Int J Hematol       Date:  2011-09-23       Impact factor: 2.490

Review 3.  Cellular and clinical pharmacology of fludarabine.

Authors:  Varsha Gandhi; William Plunkett
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 5.  Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.

Authors:  Jennifer Davila; Emily Slotkin; Thomas Renaud
Journal:  Paediatr Drugs       Date:  2014-04       Impact factor: 3.022

6.  Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.

Authors:  Paolo Anderlini; Juan Wu; Iris Gersten; Marian Ewell; Jakob Tolar; Joseph H Antin; Roberta Adams; Sally Arai; Gretchen Eames; Mitchell E Horwitz; John McCarty; Ryotaro Nakamura; Michael A Pulsipher; Scott Rowley; Eric Leifer; Shelly L Carter; Nancy L DiFronzo; Mary M Horowitz; Dennis Confer; H Joachim Deeg; Mary Eapen
Journal:  Lancet Haematol       Date:  2015-09-02       Impact factor: 18.959

7.  Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.

Authors:  V Gandhi; L E Robertson; M J Keating; W Plunkett
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Fludarabine in the treatment of chronic lymphocytic leukemia: a review.

Authors:  Francesca Ricci; Alessandra Tedeschi; Enrica Morra; Marco Montillo
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

10.  Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.

Authors:  Ann Janssens; Marc Boogaerts; Gregor Verhoef
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.